Pharmacokinetics of Six Active Components in Shuganning Injection
10.13422/j.cnki.syfjx.20260901
- VernacularTitle:舒肝宁注射液中6种活性成分的药代动力学探讨
- Author:
Qing ZHANG
1
;
Ningfang KANG
2
;
Yang ZENG
2
;
Feng HE
2
;
Siying CHEN
2
;
Yi CHEN
2
;
Jianqing PENG
2
;
Yueting LI
2
;
Lin ZHENG
2
;
Yong HUANG
2
;
Yang JIN
2
;
Zipeng GONG
2
Author Information
1. Shanghai Children's Medical Center Guizhou Hospital, Shanghai Jiao Tong University School of Medicine, Guiyang 550081, China
2. State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine(TCM), Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), School of Pharmacy, Guizhou Medical University, Guiyang 561113, China
- Publication Type:Journal Article
- Keywords:
Shuganning injection;
SD rats;
ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS);
pharmacokinetics
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(24):176-187
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the pharmacokinetics of six active components-scutellarin, baicalein, oroxylin A, geniposide, oroxylin A glucuronide, and baicalin-in Shuganning injection following single and multiple doses in rats, thus comparing the pharmacokinetics of Shuganning injection at different doses and under different dosing regimens. MethodsFirstly, ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was employed to establish a method for simultaneous determination of six active components-scutellarin, baicalein, oroxylin A, geniposide, oroxylin A glucuronide, and baicalinin—in rat plasma. Then, SD rats were assigned into a single-dose group and a multiple-dose group according to different dosing regimens. Each of the single-dose group and multiple-dose group were designed with low, medium, and high concentrations for tail vein injection. The rats were subjected to jugular vein cannulation, and blood samples were collected from the jugular vein at different time points before and after administration of Shuganning injection the next day, transferred into heparinized Eppendorf tubes, and centrifuged to separate plasma. Finally, the UPLC-MS/MS method was employed to determine the plasma concentrations of six active components at different time points. WinNonlin 8.2 software was used to analyze the pharmacokinetic parameters. ResultsA UPLC-MS/MS method was established for simultaneous determination of scutellarin, baicalein, oroxylin A, geniposide, oroxylin A glucuronide, and baicalinin in rat plasma and to study the pharmacokinetic characteristics at low, medium, and high concentrations after tail vein injection of Shuganning injection with single and multiple doses. The method verified that the linear relationship of each component in rat plasma samples was good (R2>0.995). The extraction recovery and matrix effect ranged from 92.12% to 112.48%. The intra-day and inter-day precision, accuracy, and stability met the requirements of biological sample analysis. For single-dose administration, the area under curve (AUC0-t) values of the six components increased with the increase in concentration, suggesting that the six components showed dose-dependent pharmacokinetic characteristics in vivo. For multiple-dose administration, compared with the single-dose group, at low concentrations, the AUC0-t and AUC0-∞ of baicalein increased, and the mean residence time (MRT0-∞) of the other five components except oroxylin A glucoronide prolonged. At medium concentrations, AUC0-t and AUC0-∞ increased, and clearance (CL) decreased. At high concentrations, the AUC0-t and AUC0-∞ of baicalein and geniposide increased, and the increase in AUC0-t may be due to the fact that the previous drug has not been completely eliminated at the next administration, resulting in a certain accumulation. It is hypothesized that the plasma concentration of Shuganning injection in SD rats may accumulate to a certain extent after seven consecutive days of administration once a day. ConclusionShuganning injection in different concentrations and different dosing regimens exhibit pharmacokinetic differences, which provides a theoretical basis for the clinical application of Shuganning Injection.